Search NLS News

NorthX Biologics has announced the appointment of Magnus Gustafsson as Chief Commercial Officer (CCO).

BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology. 

Novo Nordisk has announced plans to establish a completely new production facility in Odense, Denmark.

Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.

Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.

The PrimaryBid Offering attracted strong interest from both new and existing investors, with participation from over 200 retail investors across Norway, Denmark and Finland.

Orexo has recently entered a settlement agreement with Sun Pharmaceuticals Industries to resolve a patent litigation regarding the company's Zubsolv sublingual tablet for the treatment of opioid use disorder in the US. NLS asked Nikolaj Sørensen, CEO of Orexo, about the impact of this settlement and his thoughts on the patent litigation process and generic challenges.

Orexo has entered into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology.

With just months to go before the EU joint clinical assessment (JCA) process takes effect, the focus on what it will mean from a country perspective is intensifying.

The Finnish economy has had difficulties achieving robust growth following the financial crisis. The number of startups in the life science sector is declining and existing companies are struggling to secure funding.